Salvage Therapy — Treatment After Prior Options Fail

Salvage therapy represents a form of medical treatment given when a malignancy proves refractory to standard regimens or recurs after an initial response. In clinical oncology, frontline therapies are selected because they offer the highest statistical likelihood of eradication or long-term control. However, when these approaches prove insufficient or when tumour cells develop resistance, clinicians turn to salvage regimens to re-establish disease stability.

This approach encompasses a wide spectrum of modalities, including high-dose chemotherapy regimens, novel targeted therapies, immunotherapies, surgical resection, or localised radiotherapy. The selection of a specific salvage protocol relies heavily on prior treatments received, the duration of initial remission, the patient's overall functional status, and the underlying molecular characteristics of the residual or recurrent tumour burden.

Facing treatment failure or cancer recurrence can be emotionally challenging, making the availability of salvage therapy a crucial component of ongoing care planning. It provides patients and clinicians with structured alternatives when primary interventions stall. Understanding salvage options enables individuals to participate meaningfully in shared decision-making, weighing potential benefits against cumulative toxicities. Furthermore, discussions regarding salvage interventions encourage realistic goal setting, whether the objective remains disease eradication, durable chronic management, or symptom palliation. Evaluating these options helps ensure that subsequent care directly aligns with personal preferences, physical resilience, and therapeutic feasibility.

Determining the need for salvage therapy requires comprehensive diagnostic evaluation. Restaging procedures typically involve imaging modalities such as contrast-enhanced CT, MRI, or PET-CT scans to measure tumour recurrence or progression. Repeat tissue biopsies or liquid biopsies often assess emergent drug-resistance mutations, such as secondary EGFR or ALK alterations in lung cancer or ESR1 mutations in breast cancer. Blood-based tumour markers, including CA-125, PSA, or serum paraproteins, also help monitor treatment failure and guide salvage selection.

Salvage therapy is frequently discussed in haematological malignancies, including relapsed or refractory Hodgkin lymphoma, diffuse large B-cell lymphoma, acute leukaemias, and multiple myeloma. In solid tumours, it commonly features in the management of recurrent germ cell tumours, ovarian carcinoma, advanced non-small cell lung cancer, metastatic colorectal cancer, and recurrent prostate cancer. Across these diverse disease types, salvage interventions are tailored according to the primary tumour biology and previous therapeutic exposure.

Implementing salvage therapy alters the therapeutic trajectory, often transitioning patients to second-line or third-line protocols. These may include intensive chemotherapy followed by autologous or allogeneic stem cell transplantation, particularly in lymphomas. In solid tumours, salvage strategies frequently employ targeted agents, antibody-drug conjugates, or immune checkpoint inhibitors. Alternatively, patients may be evaluated for phase I or II clinical trials testing novel therapeutic mechanisms when approved salvage protocols are limited.